Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AB-218
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AB-218
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable